Showing results (151-160 of 270) with videos related to

Sort By:
Pageof 27
Lung Cancer (Amsterdam, Netherlands)|May 19, 2024
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancerEnriqueta Felip, Giulio Metro, Daniel S W Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2021
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-AnalysisFrancesco Passiglia, Michela Cinquini, Luca Bertolaccini, et al.
JAMA Network Open|February 16, 2023
Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With CancerChiara A Cella, Maren Knoedler, Marcia Hall, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief ReportXiuning Le, Christina Baik, Byoung Chul Cho, et al.
British Journal of Cancer|April 4, 2024
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISIONTerufumi Kato, James Chih-Hsin Yang, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2021
Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II TrialYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Research Square|May 27, 2024
Joint multi-omics discriminant analysis with consistent representation learning using PANDAMuhammad Aminu, Lingzhi Hong, Natalie Vokes, et al.
ESMO Open|October 17, 2020
Understanding EGFR heterogeneity in lung cancerAntonio Passaro, Umberto Malapelle, Marzia Del Re, et al.
The Oncologist|May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland CancersXiuning Le, Christina Baik, Jessica Bauman, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARDZofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
Pageof 27